We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems. However, a detailed protocol for generating and systemically delivering novel AAV variants was not previously available. In this protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifically label and/or genetically manipulate cells in the nervous system and organs, including the heart. The procedure comprises three separate stages: AAV production, intravenous delivery, and evaluation of transgene expression. The protocol spans 8 d, excluding the time required to assess gene expression, and can be readily adopted by researchers with basic molecular biology, cell culture, and animal work experience. We provide guidelines for experimental design and choice of the capsid, cargo, and viral dose appropriate for the experimental aims. The procedures outlined here are adaptable to diverse biomedical applications, from anatomical and functional mapping to gene expression, silencing, and editing.
Introduction
Recombinant AAVs (rAAVs) are commonly used vehicles for in vivo gene transfer and promising vectors for therapeutic applications 1 . However, AAVs that enable efficient and noninvasive gene delivery to defined cell populations are needed. Current gene delivery methods (e.g., intraparenchymal surgical injections) are invasive, and alternatives such as intravenous administration require high viral doses and provide relatively inefficient transduction of target cells. We previously developed Cre recombination-based AAV targeted evolution (CREATE) to engineer and screen for AAV capsids that are capable of more efficient gene transfer to specific cell types via the vasculature [2] [3] [4] . Compared to naturally occurring capsids (e.g., AAV9), the novel AAV-PHP capsids identified by CREATE exhibit markedly improved tropism for cells in the adult mouse central nervous system (CNS), peripheral nervous system (PNS), and visceral organs. In this protocol, we describe how to package genetic cargo into AAV-PHP capsids and intravenously administer AAVs for efficient, noninvasive, and targeted gene delivery at sites throughout the body (Fig. 1) .
Among our new capsid variants [2] [3] [4] , AAV-PHP.B and the further evolved AAV-PHP.eB efficiently transduce neurons and glia throughout the CNS (Fig. 2) ; another variant, AAV-PHP.S, displays improved tropism for neurons within the PNS (Fig. 3) and organs, including the gut 2 and heart (Fig. 4) . Importantly, these capsids target cell populations that are normally difficult to access because of their location (e.g., sympathetic, nodose, dorsal root, and cardiac ganglia) (Figs. 3a-c and 4d) or broad distribution (e.g., throughout the brain or enteric nervous system) (Figs. 2 and 3d) and can be utilized in several mouse and rat strains (Fig. 5) . Together with the capsid, the genetic cargo (or rAAV genome) can be customized to control transgene expression ( Fig. 6 and Table 1 ). The rAAV genome contains the components required for gene expression, including promoters, transgenes, proteintrafficking signals, and recombinase-dependent expression schemes. Hence, different capsid-cargo combinations create a versatile AAV toolbox for genetic manipulation of diverse cell populations in wild-type and transgenic animals. Here, we provide researchers, especially those new to working with AAVs or systemic delivery, with resources that will help them utilize AAV-PHP viruses in their own research.
Overview of the protocol
We provide an instruction manual for users of AAV-PHP variants. The procedure includes three main stages ( Fig. 1 ): AAV production (Steps 1-42), intravenous delivery (Steps [43] [44] [45] [46] [47] [48] [49] , and evaluation of transgene expression (Step 50).
The AAV production protocol is adapted from established methods. First, HEK293T cells are transfected with three plasmids [5] [6] [7] (Steps 1-3, Figs. 1 and 7): (i) pAAV, which contains the rAAV genome of interest ( Fig. 6 and Table 1 ); (ii) pUCmini-iCAP-PHP, which encodes the viral replication and capsid proteins (Table 2) ; and (iii) pHelper, which encodes adenoviral proteins necessary for replication. Using this triple-transfection approach, a single-stranded rAAV genome is packaged into an AAV-PHP capsid in HEK293T cells. AAV-PHP viruses are then harvested 8 (Steps 4-14), purified 9, 10 (Steps [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , and titered by quantitative PCR (qPCR) 11 (Steps 32-42) (Fig. 7) . Purified viruses are intravenously delivered to mice via retro-orbital injection 12 (Steps [43] [44] [45] [46] [47] [48] [49] , and gene expression is later assessed using molecular, histological, or functional methods relevant to the experimental aims (Step 50) .
This protocol is optimized to produce AAVs at high titer (≥1 × 10 13 vector genomes (vg)/ml and ≥1 × 10 12 vg/dish) and with high transduction efficiency in vivo 2, 3 .
Applications of the method
We anticipate that AAV-PHP capsids (Table 2) can be used to package rAAV genomes (contained in pAAV plasmids that are available through Addgene and elsewhere) ( Fig. 6 and Table 1 ) to enable a wide range of biomedical applications. Below, we highlight current and potential applications of this method.
Anatomical mapping
Fluorescent reporters are commonly used for cell type-specific mapping and phenotyping 2, 13, 14 (Figs. [2] [3] [4] [5] . AAV-mediated multicolor labeling (e.g., Brainbow 15 ) is especially advantageous for anatomical mapping approaches that require individual cells in the same population to be distinguished from one another. We and others have demonstrated the feasibility of this approach , from cell type-specific promoters. Genomes containing the hSyn1, MBP, or GFAP (GfABC 1 D) promoters were used to target neurons, oligodendrocytes, or astrocytes, respectively. Viruses were co-delivered by retro-orbital injection to 7-week-old C57BL/6N mice (n = 2) at 3 × 10 11 vector genomes (vg)/virus (9 × 10 11 vg total). Native fluorescence in coronal brain sections was evaluated 4 weeks later using confocal microscopy. All sections were mounted in Prolong Diamond Antifade before imaging. a, Cell type-specific, nuclear-localized XFPs label distinct cell types throughout the brain. Tile scan of a coronal brain slice, presented as a maximum-intensity projection; inset shows a zoomed-in view of the hippocampus. XFPs were mNeonGreen (mNG; green), tdTomato (tdT; red), and mTurquoise2 (mTurq2; blue). Scale bars, 1 mm and 500 µm (inset). b,c, Antibody staining can be used to determine the specificity and efficiency of cell type-specific promoters. b, Brain sections were stained with NeuN (purple), Olig2 (light blue), and S100 (purple) to mark neurons, oligodendrocyte lineage cells, and a population of glia that consists mainly of astrocytes, respectively. NLS-mNG (green), NLS-tdT (red), and NLS-mTurq2 (dark blue) indicate nuclear-localized XFPs. Images are from a single z plane. Scale bar, 100 µm. c, AAV-PHP.eB differentially transduces various regions and cell types throughout the brain. 'Specificity' or 'Efficiency' are defined as the ratio of double-labeled cells to the total number of XFP-or antibody-labeled cells, respectively. For image processing, median filtering and background subtraction using morphological opening were first applied to each image to reduce noise and correct imbalanced illumination. Each nucleus expressing XFPs and labeled with antibodies was then segmented by applying a Laplacian of Gaussian filter to the pre-processed images. We considered cells that were both expressing XFPs and labeled with antibodies if the nearest center-to-center distance between blobs (nuclei or cell bodies) in two channels was <7 µm (half of the cell body size). Five images per brain region were analyzed in each mouse; we excluded images with tissue edges because bright edges prevent accurate cell detection. Mean ± s.e.m. is shown. d,e, miRNA target sequences (TS) miR-204-5p or miR-708-5p 77 can be used to achieve expression that is more restricted to neurons or astrocytes, respectively. d, The indicated pairs of vectors were separately packaged into AAV-PHP.eB and co-administered via retro-orbital injection to 6-to 8-week-old C57BL/6J mice (n = 2) at 1 × 10 11 vg/virus (2 × 10 11 vg total); mNG and control XFP fluorescence were evaluated 3 weeks later using confocal microscopy. The CAG-mNG genome (green) contained no miRNA TS (left) or three tandem copies of miR-204 (middle) or miR-708 (right) TS; the CAG-XFP genome (magenta) contained no miRNA TS and was injected as an internal control. miR-204 reduced expression in cells with the morphology of astrocytes, and miR-708 reduced expression in cells with neuronal morphology. Scale bar, 100 µm. e, ssAAV-PHP.eB:CAG-GCaMP6f-3x-miR122-TS (left) or ssAAV-PHP.eB:CAG-GCaMP6f-3x-miR204-5p-3x-miR122-TS (right) was injected into 6-to 8-week-old C57BL/6J mice (n = 2) at 1 × 10 11 vg/mouse; gene expression was evaluated 3 weeks later using confocal microscopy. The miR-204 TS reduced GCaMP6f expression (green) in S100
+ glia (magenta) in the cortex. Both vectors contained three tandem copies of miR-122 to reduce expression in hepatocytes 78 . Insets and asterisks highlight representative images of S100 + glia. Scale bars, 50 µm and 10 µm (insets). Refer to Table 1 for details of rAAV genomes. Experiments on vertebrates conformed to all relevant governmental and institutional regulations and were approved by the Institutional Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the California Institute of Technology. In our primary publication 2 , results were obtained using the C57BL/6J mouse line. pA, polyadenylation signal; W, WPRE.
in the brain 2, 15 , retina 15 , heart (Fig. 4b,c) , and gut 2 , as well as the peripheral ganglia (Fig. 3c ). Spectrally distinct labeling is well-suited for studying the organization of cells (e.g., cardiomyocytes (Fig. 4b) ) in healthy and diseased tissues and long-range tract tracing of individual fibers through extensive neural networks (e.g., the enteric 2 or cardiac nervous systems (Fig. 4c) ).
Functional mapping AAV-PHP capsids are also relevant for probing cell function. AAV-PHP.B was previously used to target distinct neural circuits throughout the brain for chemogenetic 16, 17 and optical imaging applications 18, 19 . We predict that AAV-PHP viruses will be beneficial for manipulating neural networks that are typically difficult to access, such as peripheral circuits controlling the heart (Fig. 4d ), lungs 20 , or gut 21 . AAV-PHP variants could also be utilized to interrogate the function of non-neuronal cell types, including cardiomyocytes 22 , pancreatic beta cells 23, 24 , and hepatocytes 25 . Harnessing AAV-PHP viruses to modulate cell physiology may reveal novel roles for different cells in regulating organ function and/or animal behavior 26 . We used AAV-PHP.S to package single-stranded (ss) rAAV genomes that express fluorescent reporters from either neuron-specific (e.g., hSyn1 and TH (tyrosine hydroxylase)) or ubiquitous promoters (e.g., CAG). Viruses were delivered by retro-orbital injection to 6-to 8-weekold C57BL/6J or Cre transgenic mice, and transgene expression was evaluated 2-3 weeks later. Whole-mount tissues were optically cleared using either ScaleSQ 64 (a (right), c, and d) or RIMS 57 (b) and imaged using wide-field or confocal microscopy; confocal images are presented as maximum-intensity projections. a, ssAAV-PHP.S:hSyn1-mNeonGreen and ssAAV-PHP.S:CAG-DIO-mRuby2 were co-injected into a TH-IRES-Cre mouse at 1 × 10 12 vg/virus (2 × 10 12 vg total). Native mNeonGreen (green) and mRuby2 (red) fluorescence were assessed 2 weeks later using wide-field (left) or confocal fluorescence microscopy (right). Images are from the second to sixth thoracic (T2-T6) (left) and eighth cervical to second thoracic (C8-T2) (right) paravertebral ganglia, which provide sympathetic innervation to thoracic organs, including the heart. Arrows denote mNeonGreen + nerve fibers. Scale bars, 1 mm (left) and 500 µm (right). b, ssAAV-PHP.S:CAG-DIO-eYFP was injected into a TRPV1-IRES-Cre mouse at 1 × 10 12 vg; gene expression in a nodose ganglion was evaluated 3 weeks later. Scale bar, 200 µm. c, A mixture of three separate viruses (ssAAV-PHP.S:CAG-DIO-XFPs) was injected into a TRPV1-IRES-Cre mouse at 1 × 10 12 vg/virus (3 × 10 12 vg total); gene expression in a dorsal root ganglion was evaluated 2 weeks later. XFPs were mTurquoise2 (blue), mNeonGreen (green), and mRuby2 (red). Scale bar, 200 µm. d, ssAAV-PHP.S:mTH-GFP and ssAAV-PHP.S:hSyn1-tdTomato-f (farnesylated) were co-injected into a C57BL/6J mouse at 5 × 10 11 vg/virus (1 × 10 12 vg total); gene expression in the duodenum was assessed 22 d later. The image stack includes both the myenteric and submucosal plexuses. Inset shows a zoomed-in view of ganglia containing TH + cell bodies (green); tdTomato-f (red) labels both thick nerve bundles and individual fibers. Scale bars, 200 µm (left) and 50 µm (right). Refer to Table 1 for details of rAAV genomes. Experiments on vertebrates conformed to all relevant governmental and institutional regulations and were approved by the Institutional Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the California Institute of Technology. In our primary publication 2 , results were obtained using the ChAT-IRES-Cre driver mouse line.
Gene expression, silencing, and editing AAV-PHP viruses can be used to test potential therapeutic strategies that would benefit from organwide or systemic transgene expression 27 . Recently, AAV-PHP.B was used to treat 16 and model 28 neurodegenerative diseases with widespread pathology. Other potential applications include gene editing (e.g., via CRISPR [29] [30] [31] [32] ) or silencing (e.g., via shRNA 33 ); importantly, these approaches could be utilized to broadly and noninvasively manipulate cells in both healthy and diseased states for either basic research or therapeutically motivated studies.
AAV capsid engineering AAV-PHP capsids can be further evolved for more efficient transduction of specific organs and cell types throughout the body. This protocol can be used for AAV engineering applications (e.g., our in vivo capsid selection method CREATE 2, 3 ). Using a modified transfection protocol (Steps 1-3 and online methods in ref.
3 ), DNA libraries (generated by diversification of the AAV cap gene) are packaged to produce AAV capsid libraries, which are then harvested (Steps 4-14 and online methods in ref.
3 ), purified (Steps 15-31), and titered (Steps 32-42). Libraries are systemically administered to Cre transgenic animals (Steps 43-49) or wild-type animals in which Cre is introduced (e.g., by AAV S for mapping the anatomy and physiology of the heart. AAV-PHP.S viruses were delivered by retro-orbital injection to 6-to 8-week-old C57BL/6J or Cre transgenic mice. a, AAV-PHP.S transduces the heart more efficiently than the current standard, AAV9. ssAAV9:CAG-NLS-GFP or ssAAV-PHP.S:CAG-NLS-GFP were injected into C57BL/6J mice at 1 × 10 12 vg/mouse. Native GFP fluorescence was assessed in whole-mount hearts 4 weeks later using wide-field fluorescence microscopy (unpaired t test, t 7 = 8.449, **** P <0.0001). For AAV9 and AAV-PHP. S, n = 5 and 4 mice, respectively. a.u., arbitrary units. Mean ± s.e.m. is shown. Scale bar, 3 mm. b, A mixture of three viruses (ssAAV-PHP.S:CAG-XFPs) was injected into a C57BL/6J mouse at 3.3 × 10 11 vg/virus (1 × 10 12 vg total); gene expression in cardiac muscle was evaluated 11 d later. Individual cardiomyocytes can be easily distinguished from one another. Scale bar, 200 µm. c, A mixture of three viruses (ssAAV-PHP.S:CAG-DIO-XFPs) was injected into a TRPV1-IRES-Cre mouse at 1 × 10 12 vg/virus (3 × 10 12 vg total); gene expression in cardiac nerves was evaluated 2 weeks later. Scale bar, 50 µm. d, ssAAV-PHP.S:Ef1ɑ-DIO-ChR2-eYFP was injected into ChAT-IRES-Cre mice (n = 2) at 1 × 10 12 vg; gene expression in a cardiac ganglion was evaluated 3 weeks later (left). Ex vivo intracellular recordings were performed after 5 weeks of expression. Differential interference contrast (DIC) image (middle) shows the optical fiber for light delivery and electrode for concurrent intracellular recordings; inset shows a highermagnification image of a selected cell (asterisk). Cholinergic neurons generated action potentials in response to 473-nm light pulses (5 Hz, 20 ms) (right). Scale bars, 50 µm (left), 300 µm (middle), and 10 µm (inset). Wholemount tissues in b, c, and d (left) were optically cleared using ScaleSQ 64 and imaged using confocal microscopy; confocal images are presented as maximum-intensity projections. XFPs in b and c were mTurquoise2 (blue), mNeonGreen (green), and mRuby2 (red). Refer to Table 1 for details of rAAV genomes. The pAAV-Ef1ɑ-DIO-ChR2-eYFP plasmid was a gift from K. Deisseroth, Stanford University (Addgene, plasmid no. 20298). Experiments on vertebrates conformed to all relevant governmental and institutional regulations and were approved by the Institutional Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the California Institute of Technology. In our primary publication delivery), and Cre-dependent cap recovery from tissues of interest facilitates further rounds of selection to isolate enriched variants. This protocol can also be used to characterize novel serotypes identified with CREATE or other engineering methods 34 . B and AAV-PHP.eB can be used in several mouse and rat strains. a, AAV-PHP.B transduces the brain more efficiently than AAV9 in C57BL/6J, FVB/NCrl, and 129S1/SvImJ mice, but not in BALB/cJ mice. ssAAV9:CAG-mNeonGreen or ssAAV-PHP.B:CAG-mNeonGreen were systemically delivered to 6-to 8-week-old C57BL/6J (n = 1-2 mice per group), FVB/NCrl (n = 2 mice per group), 129S1/SvImJ (n = 2 mice per group), and BALB/cJ mice (n = 2 mice per group) at 1 × 10 12 vg/mouse. 3 weeks later, sagittal brain sections were mounted in Vectashield and imaged using confocal microscopy. Imaging and display parameters are matched across all panels. Scale bar, 2 mm. b-e, Examples of AAV-PHP.B-and AAV-PHP.eB-mediated brain transduction for fluorescent labeling (b,c) and calcium imaging (d,e) in different mouse and rat strains. Gene expression was evaluated using confocal microscopy. b, ssAAV-PHP.eB:CAG-tdTomato (Addgene) was delivered by retro-orbital injection to a 10-week-old 129T2/SvEmsJ mouse at 3 × 10 11 vg; tdTomato fluorescence (red) was examined 2 weeks later. Scale bars, 1 mm (top) and 100 µm (insets). c, ssAAV-PHP.eB:CAG-mRuby2 was administered by tail-vein injection to a 6-week-old female Fischer rat at 3 × 10 12 vg; 3 weeks later, brain slices were mounted in Prolong Diamond Antifade for imaging. Scale bars, 2 mm (top) and 100 µm (insets). d, ssAAV-PHP.eB:CMV-hSyn1-GCaMP6f-3x-miR122-TS was delivered by tail-vein injection to a 4-week-old female Long-Evans rat at 1 × 10 13 vg; 3 weeks later, brain slices were stained with a GFP antibody (green) for imaging. Scale bars, 1 mm (top left) and 100 µm (insets). The vector contained three tandem copies of miRNA target sequence (TS) miR-122 (CAAACACCATTGTCACACTCCA) to reduce expression in hepatocytes 78 . Images in d courtesy of M. Fabiszak/W. Freiwald lab, Rockefeller University. e, ssAAV-PHP.B:CaMKIIa-CaMPARI (calcium-modulated photoactivatable ratiometric integrator 79 ) was administered by retro-orbital injection to a 8-week-old FVB/NCrl mouse at 3 × 10 11 vg and cortical expression was assessed 2 weeks later. Images are a 50-µm maximum-intensity projection of the cortex (left) and 500-µm-thick ScaleSQ 64 -cleared 3D volume (right). Scale bars, 100 µm. Experiments on vertebrates conformed to all relevant governmental and institutional regulations and were approved by the Institutional Animal Care and Use Committee (IACUC) and the Office of Laboratory Animal Resources at the California Institute of Technology. In our primary publication 2 , results were obtained using the C57BL/6J mouse line. CaMKIIa, calcium/calmodulin-dependent protein kinase type IIa; CMV, cytomegalovirus early enhancer element.
Limitations of the method
A major limitation of AAV capsids, including AAV-PHP variants, is their relatively small packaging capacity (<5 kb). Some elements of the rAAV genome, such as the woodchuck hepatitis posttranscriptional regulatory element (WPRE), can be truncated 35 or removed 36, 37 to accommodate larger genetic components. The development of smaller promoters 38, 39 and dual expression systems 40 , in which genetic elements are split between two or more viruses (requiring efficient cotransduction), has also enabled the delivery of larger genomes. Continued development of these approaches will help bypass restrictions on rAAV genome size.
Intravenous administration of AAVs also presents unique challenges. For example, systemic transduction may be undesirable for applications in which highly restricted gene expression is vital to the experimental outcome. Possible off-target transduction, due to the broad tropism of AAV-PHP variants and/or lack of compatible cell type-specific promoters, can be reduced by miRNA-mediated gene silencing. Sequences complementary to miRNAs expressed in off-target cell populations can be introduced into the 3ʹ UTR of the rAAV genome (Fig. 6) ; this has been shown to reduce off-target transgene expression and better restrict expression to cell types of interest 41, 42 (Fig. 2d,e) . Another challenge of systemic delivery is that it requires a high viral load, which can elicit an immune response against the capsid and/or transgene and reduce transduction efficiency in vivo 43 . Immunogenicity of AAVs may be exacerbated by empty capsid contamination in viral preparations 44, 45 . The viral purification protocol (Steps 15-31) reduces, but does not eliminate, empty capsids (Fig. 7b) . If this poses a concern for specific applications, viruses can be purified using an alternative approach 8, 9, 46 . Last, generation of viruses for systemic administration may impose a financial burden on laboratories due to the doses of virus required. Nevertheless, viral-mediated gene delivery is inexpensive compared to creating and maintaining transgenic animals. Moreover, intravenous injection is faster, less invasive, and less technically demanding than other routes of AAV administration, such as stereotaxic injection, thereby eliminating the need for specialized equipment and survival surgery training.
Experimental design
Before proceeding with the protocol, a number of factors should be considered, namely the expertise and resources available in the lab; the animal model, capsid, and rAAV genome to be used; the dose (Fig. 2d,e) , determine the strength and specificity of transgene expression 54 . Transgenes may be constitutively expressed or flanked by recombination sites for flippase (Flp)-or Cre recombinase (Cre)-dependent expression. In the latter approach, the transgene remains in the double-floxed inverted orientation (DIO); Cre-mediated inversion of the transgene enables cell type-specific expression in transgenic animals (Figs. 3a-c and 4c,d). Localization sequences further restrict gene expression to distinct cellular compartments such as the nucleus (via one or more nuclear localization signals (NLS)) (Fig. 2a,b) , cytosol (via a nuclear exclusion signal (NES) 80 ), or cell membrane (via farnesylation 76 , the CD4-2 81 transmembrane (TM) targeting domain, or PDZ 82 protein-protein interaction domains) (Fig. 3d) . Note that the 3ʹ UTR contains the woodchuck hepatitis posttranscriptional regulatory element (WPRE) (609 bp) and a polyadenylation signal (e.g., the human growth hormone (hGH) polyA) (479 bp) (not shown), both of which enhance transgene expression 54 . We recommend that foreign genes be codon-optimized to match the host species to increase expression from the rAAV genome. Use sequence-editing and annotation software to determine the unique attributes of each rAAV genome. In Table 1 , we list genomes used here and in our previous work 2, 3 ; see also Addgene's plasmid repository for pAAVs that may be suitable for different applications. CRISPR, clustered regularly interspaced short palindromic repeats; DREADDs, designer receptors exclusively activated by designer drugs; shRNA, short hairpin RNA.
for intravenous administration; and the method(s) available for assessing transgene expression. Each of these topics is discussed below to guide users in designing their experiments.
Required expertise and resources
This protocol requires that the scientists have basic molecular biology, cell culture, and animal work experience. Users should be approved to handle laboratory animals, human cell lines, and AAVs. A background in molecular cloning is advantageous, although not necessary if relying on available plasmids.
In addition to having the above expertise, the labs must be equipped for the molecular and cell culture work relevant to the procedure; we suggest that users read through the entire 'Materials' and 'Procedure' sections beforehand to ensure that the required reagents and equipment are available and appropriate safety practices and institutional approvals are in place. (Fig. 3) , TRPV1-IRESCre (Figs. 3 and 4) , and ChAT-IRES-Cre mice 2 (Fig. 4) . Intriguingly, AAV-PHP.B demonstrates low transduction throughout the brain when systemically administered to BALB/cJ mice 48 ( Fig. 5a ). However, the neurotropic properties of AAV-PHP.B are not limited to the C57BL/6J strain in which they were selected. AAV-PHP.B transduces the brain more efficiently than AAV9 in both FVB/NCrl and 129S1/SvImJ mice (Fig. 5a ). We also show examples of AAV-PHP.eB transducing neurons in C57BL/6NCrl (Fig. 2a-c) and 129T2/SvEmsJ mice (Fig. 5b) , as well as Fischer (Fig. 5c ) and LongEvans rats (Fig. 5d ). Compared to AAV9 and AAV-PHP.B, AAV-PHP.eB results in more efficient neuronal transduction in Sprague-Dawley rats after either intravenous administration or intraparenchymal stereotaxic injections 28, 49 . We predict that AAV-PHP capsids can be used in multiple species and strains for diverse applications, such as those requiring fluorescent labeling (Fig. 5a-c ) and calcium imaging (Fig. 5d,e) . We have not compared the transduction efficiencies of AAV9
Day
Step Procedure (Fig. 1) . b, Schematic of the AAV harvest procedure, with images corresponding to indicated steps. The iodixanol-based purification protocol does not eliminate empty capsids (i.e., capsids that fail to package an rAAV genome), as determined by negative-staining transmission electron microscopy; empty particles are characterized by an electron-dense core. Scale bar, 50 nm. Gray arrows and text denote steps at which the supernatant and pellet can be bleached and discarded (Steps 13 and 18).
and AAV-PHP capsids across all rodent strains and species or determined the optimal dose for transducing specific organs and cell types in different animal models. Users should test these parameters to determine the utility of AAV-PHP variants in their research. See 'Reagents' for mouse and rat catalog numbers.
Selecting an AAV-PHP capsid
We recommend choosing an AAV-PHP capsid (Table 2 ) based on its tropism and production efficiency. Capsid properties are listed in Supplementary Table 1 ; we include species, organs, and cell populations examined to date and note typical viral yields. We anticipate that most researchers will use AAV-PHP.eB (Addgene, plasmid no. 103005) or AAV-PHP.S (Addgene, plasmid no. 103006) in their experiments. AAV-PHP.eB and AAV-PHP.S produce viral yields similar to those of other high-producing naturally occurring serotypes (e.g., AAV9) and enable efficient, noninvasive gene transfer to the CNS or PNS and visceral organs, respectively 2 (Figs. 2-5). The earlier capsid variants, which provide widespread CNS transduction, either produce suboptimal yields (AAV-PHP.A) 3 or have since been further evolved for enhanced transduction efficiency in vivo (AAV-PHP.B (Addgene, plasmid no. 103002)) 2 . We therefore recommend using AAV-PHP.eB for CNS applications, especially when targeting neurons. Note, however, that the chosen capsid will ultimately depend on the experimental circumstances; multiple factors, including species 50 , strain 48 ( Fig. 5 ), age 51 , gender 52 , and health 53 , can influence AAV tropism. Testing the AAV-PHP variants in a variety of experimental paradigms will continue to reveal the unique attributes of each capsid and identify those most suitable for different applications.
Selecting an rAAV genome Users must select an rAAV genome, contained in a pAAV plasmid, to package into the capsid (Figs. 1 and 6; Table 1 ). In Table 1 , we list the pAAVs used here (Figs. 2-4) and in our previous work 2, 3 ; we direct users to Addgene's plasmid repository for additional pAAVs developed for various applications.
Depending on the experimental aims, users can elect to design their own genomes 54 and clone from existing pAAVs. When customizing plasmids, it is imperative that the rAAV genome, the sequence between and including the two inverted terminal repeats (ITRs), does not exceed 4.7-5 kb (Fig. 6) ; larger genomes will not be fully packaged into AAV capsids, resulting in truncated genomes and low titers. The ITRs are 145-bp sequences that flank the expression cassette and are required for replication and encapsidation of the viral genome. ITRs are typically derived from the AAV2 genome and must match the serotype of the rep gene contained in the capsid plasmid; pUCmini-iCAP-PHP plasmids contain the AAV2 rep gene and are therefore capable of packaging genomes with AAV2 ITRs (i.e., almost any pAAV available from Addgene). Other genetic components (e.g., promoters, transgenes, localization signals, and recombination schemes) are interchangeable and can be customized for specific applications (Fig. 6 ).
Dosage for intravenous administration
The optimal dose for intravenous administration to target cell populations must be determined empirically. We encourage users to refer to Figs. 2-5 and related work for suggested AAV-PHP viral AAV-PHP capsid plasmids have a built-in tTA-TRE-based inducible amplification loop to increase virus production. If the rAAV genome has a tetracycline-regulated element (e.g., TRE), the tTA on the capsid plasmid will drive a high level of expression from the TRE-containing rAAV genome, which may reduce virus production. To increase viral yields, increase the number of dishes per viral prep. a Given the poor production efficiency of AAV-PHP.A, and its tendency to aggregate after purification, we suggest using AAV-PHP.eB to target astrocytes. Use an astrocyte promoter, such as GFAP, to drive transgene expression ( Fig. 2a-c 18, 19 and optogenetic ( Fig. 4d ), chemogenetic 16, 17 , and therapeutic applications 16, 28 . We typically administer between 1 × 10 11 and 5 × 10 11 vg of AAV-PHP.eB or between 3 × 10 11 and 1 × 10 12 vg of AAV-PHP.S to adult mice (6-8 weeks old). However, dosage will vary depending on the target cell population, desired fraction of transduced cells, and expression level per cell. AAVs independently and stochastically transduce cells, typically resulting in multiple genome copies per cell 2 . Therefore, higher doses generally result in strong expression (i.e., high copy number) in a large fraction of cells, whereas lower doses result in weaker expression (i.e., low copy number) in a smaller fraction of cells. To achieve high expression in a sparse subset of cells, users can employ a two-component system in which transgene expression is dependent on co-transduction of an inducer (e.g., a vector expressing Cre 55 , Flp 2 , or the tetracycline-controlled transactivator (tTA) 2 ); inducers are injected at a lower dose (typically 1 × 10 9 to 1 × 10 11 vg) to limit the fraction of cells with transgene expression. Note that transgenes and gene regulatory elements (e.g., enhancers, promoters, and miRNA target sequences (Fig. 2d,e) ) can influence gene expression levels. Therefore, users should assess transgene expression from a series of doses and at several time points after intravenous delivery to determine the optimal experimental conditions.
Evaluation of transgene expression
Following in vivo delivery, AAV transduction and transgene expression increase over the course of several weeks. Although expression is evident within days after transduction, it does not reach a steady-state level until at least 3-4 weeks after transduction. Therefore, we suggest waiting for a minimum of 2 weeks before evaluating fluorescent labeling 2,3,16,28 (Figs. 2-5) and at least 3-4 weeks before beginning optogenetic (Fig. 4d ), chemogenetic 16, 17 , and calcium imaging 18, 19 experiments. Note that, like other AAVs, AAV-PHP variants are capable of providing long-term transgene expression. AAV-PHP.B-mediated cortical expression of a genetically encoded calcium indicator, GCaMP6s, was reported to last at least 10 weeks post-injection without toxic side effects 19 (i.e., nuclear filling 56 ), and we have observed GFP expression throughout the brain >1 year after viral administration (see Supplementary Fig. 4 in ref.
3 ). However, the time points suggested here are only meant to serve as guidelines; gene expression is contingent on multiple factors, including the animal model, capsid, genome, and dose.
The appropriate method(s) for evaluating transgene expression will vary among users and may include functional (e.g., optical imaging 56 ), histological 57 (e.g., using endogenous fluorescence, antibodies, or molecular probes), or molecular (e.g., Western blot 58 or qPCR 3 ) approaches 59 . To assess transduction efficiency across different organs, users can perform a qPCR-based vector biodistribution assay, in which vector genomes are quantified and normalized to the mouse genome (e.g., a housekeeping gene) 3 . Other approaches typically involve examining fluorescent protein expression in thin or thick (≥100 µm) tissue samples. The CLARITY-based methods such as passive CLARITY technique (PACT) and perfusion-assisted agent release in situ (PARS) 60 render thick tissues optically transparent while preserving their three-dimensional molecular and cellular architecture, and facilitate deep imaging of large volumes (e.g., using confocal or light-sheet microscopy) [61] [62] [63] . Cleared tissues are compatible with endogenous fluorophores, including commonly used markers such as GFP 3, 57, 60 , eYFP 60 , and tdTomato 57 . However, some fluorescent signals, such as those from mTurquoise2, mNeonGreen, and mRuby2, can deteriorate in chemical clearing reagents. To visualize these reporters, we suggest using optical clearing reagents such as refractive index-matching solution (RIMS) 57 or ScaleSQ 64 (Figs. 3a,c,d, 4b-d, and 5e) or commercially available mounting media (Step 50) (Fig. 5a,c) . Some fluorescent proteins are sensitive to photobleaching. For example, mRuby2 may bleach over long imaging sessions or at high magnification; tdTomato exhibits similar spectral properties and may be a more suitable alternative, given its photostability 65 . Also, note that autofluorescent lipofuscin accumulates in aging postmitotic tissues (e.g., the brain and heart) 66 and may interfere with examination of transduced cells; in this case, either reduce autofluorescence using histological methods 57, 67 or, if possible, inject younger adults (≤8 weeks old) and determine the minimum time required for transgene expression.
Materials Biological materials
! CAUTION To address the issue of cell line misidentification and cross-contamination, it is recommended that cell lines be regularly checked to ensure they are authentic and are not infected with mycoplasma.
• Plasmids, supplied as bacterial stabs (Addgene; see Tables 1 and 2 for plasmids used in this and related work) c CRITICAL Three plasmids (pAAV, pUCmini-iCAP-PHP, and pHelper) are required for transfection (Fig. 1) . The pHelper plasmid is available in Agilent's AAV helper-free kit (Agilent, cat. no. 240071).
• Human embryonic kidney (HEK) cells (293 or 293T; ATCC, cat. no. CRL 1573 or CRL 3216, respectively) ! CAUTION HEK cells pose a moderate risk to laboratory workers and the surrounding environment and must be handled according to governmental and institutional regulations. Experiments involving HEK cells were performed using biosafety level 2 practices as required by the California Institute of Technology and the US Centers for Disease Control and Prevention. c CRITICAL HEK293 and HEK293T cells constitutively express two adenoviral genes, E1a and E1b, which are required for AAV production in these cells 7 ; we do not recommend using an alternative producer cell line with this protocol.
• Plasmid DNA containing the target sequence to be amplified during AAV titration; used for preparing the DNA standard stock c CRITICAL The plasmid used to make the DNA standard must contain the same target sequence as the pAAV plasmid used to generate virus. The target sequence must be within the rAAV genome; we typically amplify a portion of the WPRE or hGH polyA (see Fig. 6 caption for abbreviations and 'Reagents' for primer sequences).
• Animals to be injected. Step 16 Step 16 Step 18
Step 19 Spacer e
Step 19
Steps 24-25
Step 26
Step 27 • Reagent setup c CRITICAL All reagents used for viral production and administration should be prepared using endotoxin-free materials. Glassware is not endotoxin-free, and autoclaving does not eliminate endotoxins. To minimize contamination, we dissolve chemicals in sterile bottles by shaking and/or heating to mix, use demarcations on bottles to bring solutions to the final volume, and use pH strips rather than a pH meter. When filter-sterilizing solutions, do so in a biosafety cabinet.
Plasmid DNA Grow bacterial stocks in LB or Plasmid+ media containing the appropriate selective antibiotic; refer to the Addgene catalog for suggested growth conditions. Use a large-scale endotoxin-free plasmid purification kit to isolate plasmids; elute plasmid DNA with the supplied Tris-EDTA (TE) buffer. Measure the DNA purity and concentration using a spectrophotometer and freeze at −20°C or −80°C for up to several years. c CRITICAL Always verify the integrity of purified plasmids by Sanger sequencing (using a DNA sequencing facility) and restriction digestion (https://www.neb.com/tools-a nd-resources) before proceeding with downstream applications. pAAV plasmids contain ITRs (Fig. 6 ) that are prone to recombination in E. coli. pAAVs should be propagated in recombination-deficient strains such as NEB Stable, Stbl3, or SURE 2 competent cells to prevent unwanted recombination. After purification, pAAVs should be digested with SmaI to confirm the presence of ITRs, which are required for replication and encapsidation of the viral genome; use sequence-editing and annotation software to determine the expected band sizes. Note that it is difficult to sequence through the secondary structure of ITRs 68 ; avoid ITRs when designing sequencing primers. c CRITICAL Create bacterial glycerol stocks and store at -80°C for up to several years.
Cell culture media Add 25 ml of FBS, 5 ml of NEAA, and 5 ml of pen-strep to a 500-ml bottle of DMEM. Invert to mix and store at 4°C for up to several months; warm to 37°C before use. The resulting cell culture media should have a final concentration of 5% (vol/vol) FBS, 1× NEAA, and 50 U/ml pen-strep. c CRITICAL To quickly expand cells for large viral preps, consider using a final concentration of 10% (vol/vol) FBS in the cell culture media; see guidelines on cell culture below.
Cell culture Thaw HEK293T cells according to the manufacturer's recommendations. Passage cells using either TrypLE Express enzyme or a standard trypsinization protocol for adherent cultures 69 . Seed cells in 150-mm tissue culture dishes with a final volume of 20 ml of media per dish. Maintain in a cell culture incubator at 37°C with 5% CO 2 .
c CRITICAL We suggest passaging cells at a ratio of 1:3 (i.e., divide one dish of cells into three new dishes of cells) every other day when expanding cells for viral production; split cells at a 1:2 ratio (or 6 × 10 4 cells/cm 2 ) 24 h before transfection. Use higher split ratios if using 10% (vol/vol) FBS. Always use sterile technique. c CRITICAL Follow the manufacterer's recommendations to create frozen stocks of HEK cells.
PEI stock solution
Pipette 50 ml of WFI water into a 50-ml conical centrifuge tube for later use. Add 323 mg of PEI to the remaining 950 ml bottle of WFI water and adjust the pH to 2-3 by adding 1 N HCl suitable for cell culture, keeping track of the volume of HCl added. Heat in a 37°C water bath for several hours (or overnight) and occasionally shake to mix. Once dissolved, add reserved WFI water to a total volume of 1 liter. Filter-sterilize, make aliquots in 50-ml conical centrifuge tubes, and store at −20°C for up to 1 year. We routinely freeze-thaw our PEI aliquots. c CRITICAL Both our PEI stock solution recipe and PEI calculations (Supplementary Table 2 , 'Detailed calculations' sheet) are based on ref. 5 . We adjust the pH to 2-3 so that PEI dissolves in water. The designated pH range does not appear to adversely affect cell viability, transfection efficiency, or viral titers. The transfection solution, created by mixing the PEI + DPBS master mix and DNA + DPBS solution (Step 2 and Supplementary Table 2) , has a final pH of 6.5-7.0. To transfect one dish, 2 ml of transfection solution is added to 20 ml of media (Step 2), which further dilutes the PEI.
PEI + DPBS master mix
Thaw PEI in a 37°C water bath. Bring the PEI to room temperature (RT; 23°C) and vortex to mix. Add PEI and DPBS to a 50-ml conical centrifuge tube and vortex again to mix. Use Supplementary 40% (wt/vol) PEG stock solution Decant~500 ml of WFI water into a 500-ml sterile bottle for later use. Add 146.1 g of NaCl to the remaining 500 ml (in the 1-liter bottle of WFI water) and shake/heat until dissolved. Once completely dissolved, add 400 g of PEG and heat at 37°C overnight for up to 2 nights. Add reserved WFI water to a total volume of 1 liter. Filter-sterilize and store at RT for up to several months. The resulting stock solution should have a final concentration of 2.5 M NaCl and 40% (wt/vol) PEG. c CRITICAL Prepare in advance. To expedite the procedure, heat the solution at 65°C until the PEG is dissolved. The solution will appear turbid, but no flecks of PEG should remain; the mixture will become clear upon cooling. c CRITICAL Pre-wet the entire filter surface with a minimal volume of water before adding the solution. This solution is extremely viscous and will take 1-2 h to filter. DPBS + high salt Add 29.22 g of NaCl, 93.2 mg of KCl, and 101.7 mg of MgCl 2 ·6H 2 O to a 500-ml bottle of DPBS and shake to mix. Filter-sterilize and store at RT for up to several months. The resulting buffer should have a final concentration of 1 M NaCl, 2.5 mM KCl, and 1 mM MgCl 2 (in addition to the salts in the DPBS).
DPBS + low salt Add 2.92 g of NaCl, 93.2 mg of KCl, and 101.7 mg of MgCl 2 ·6H 2 O to a 500-ml bottle of DPBS and shake to mix. Filter-sterilize and store at RT for up to several months. The resulting buffer should have a final concentration of 100 mM NaCl, 2.5 mM KCl, and 1 mM MgCl 2 (in addition to the salts in the DPBS).
Iodixanol density gradient solutions (15%, 25%, 40%, and 60% (wt/vol) iodixanol) For each layer, add iodixanol (OptiPrep), DPBS + high salt or DPBS + low salt, and phenol red (if applicable) to a 50-ml conical centrifuge tube. Invert or briefly vortex to mix. Use Supplementary  Table 3 to determine the volumes of each reagent needed. The 25% and 60% layers contain phenol red, which turns the solutions red and yellow, respectively, and facilitates clear demarcation of the gradient boundaries (Fig. 8) .
c CRITICAL Prepare fresh solutions on the day of AAV purification. Alternatively, prepare up to 1 d in advance; store at RT and protect from light. Do not pour the density gradients until Step 16. c CRITICAL In
Step 16B, prepare more iodixanol solutions than are needed. For six or fewer gradients, prepare enough of each solution to pour an extra gradient. For eight gradients, prepare enough of each solution to pour two extra gradients. The extra solution is needed to fill the 5-ml pipette and prevent an air bubble from disturbing the gradient when releasing the last of the required volume.
DNase digestion buffer
Use a 50-ml serological pipette to measure 247.5 ml of UltraPure water into a 250-ml sterile bottle. Add 55.5 mg of CaCl 2 , 2.5 ml of 1 M Tris-HCl, and 508 mg of MgCl 2 ·6H 2 O and shake to mix. Filtersterilize and store at RT for up to several months. The resulting buffer should have a final concentration of 2 mM CaCl 2 , 10 mM Tris-HCl, and 10 mM MgCl 2 .
DNase I + DNase digestion buffer Add 50 U of DNase I per milliliter of digestion buffer (a 1:200 dilution of 10 U/µl DNase); pipette to mix.
c CRITICAL Prepare fresh solution before use.
Proteinase K solution
Use a 50-ml serological pipette to measure 250 ml of UltraPure water into a 250-ml sterile bottle. Add 14.61 g of NaCl and shake to mix. Add 2.5 g of N-lauroylsarcosine sodium salt to the mixture and gently swirl to mix; N-lauroylsarcosine sodium salt is a surfactant and will generate bubbles during vigorous mixing. Filter-sterilize and store at RT for up to several months. The resulting solution should have a final concentration of 1 M NaCl and 1% (wt/vol) N-lauroylsarcosine sodium salt.
Proteinase K + proteinase K solution Add 100 µg of proteinase K per milliliter of solution (a 1:200 dilution of 50 U/ml (2.5 U/mg) proteinase K); pipette to mix. c CRITICAL Prepare fresh solution before use.
DNA standard stock
Set up a single 50-µl restriction digest reaction; use 60-80 U (3-4 µl) of ScaI (or another suitable enzyme) to linearize 20 µg of the plasmid DNA containing the target sequence. Run a small amount of the reaction on an agarose gel to ensure complete digestion. Purify the reaction using two DNA clean-up columns. Measure the DNA concentration (ng/µl) using a spectrophotometer. Dilute tõ 5-10 × 10 9 single-stranded (ss) DNA molecules/µl and use the Qubit assay to verify the concentration (ng/µl). Divide into 20-µl aliquots in DNA/RNA LoBind microcentrifuge tubes and freeze at −20°C for up to 1 year. c CRITICAL Before preparing the standard, use sequence-editing and annotation software to confirm that the plasmid contains a single ScaI site in the ampicillin resistance gene.
c CRITICAL Refer to ref. 11 and use Supplementary Table 4 (cells B7-10) to calculate the number of ssDNA molecules in a given plasmid (cell B13). We typically use linearized pAAV-CAG-eYFP diluted to 10 ng/µl, which corresponds to 6.6 × 10 9 ssDNA molecules/µl (Supplementary Table 4 , 'Example' sheet).
DNA standard dilutions
Prepare three sets of eight (1:10) serial dilutions of the DNA standard stock. For each set, begin by pipetting 5 µl of the standard into 45 µl of UltraPure water (standard no. 8). Mix by vortexing for 3 s and proceed with the seven remaining dilutions (standard no. 7 to standard no. 1). The final concentrations of the standard dilutions should range from 5-10 × 10 8 (standard no. 8) to 5-10 × 10 1 (standard no. 1) ssDNA molecules/µl. c CRITICAL Prepare fresh solutions in DNA/RNA LoBind microcentrifuge tubes immediately prior to use; at low concentrations, the linearized DNA is prone to degradation and/or sticking to the walls of the tube 11 . One 20-µl aliquot of the DNA standard stock will provide enough DNA for preparing the dilutions and verifying the concentration via the Qubit assay before qPCR.
qPCR master mix Prepare a qPCR master mix for the total number of reactions (i.e., wells) needed. One reaction requires 12.5 µl of SYBR Green master mix, 9.5 µl of UltraPure water, and 0.5 µl of each primer (from a 2.5-µM stock concentration), for a total of 23 µl/well. Pipette or vortex for 1-2 s to mix. c CRITICAL Prepare fresh solution before use.
Equipment setup
Clamp setup for AAV purification Attach the rod to the support stand. Secure the clamp 25-30 cm above the stand (Fig. 8f) .
Anesthesia system
Place the induction chamber, nose cone, and waste gas scavenging system (e.g., activated charcoal adsorption filters) inside a biosafety cabinet. We recommend using an anesthesia system in which the isoflurane vaporizer and oxygen supply remain outside of the cabinet workspace. Connect the associated tubing such that the input is from the vaporizer/oxygen supply and the output is to the charcoal scavenging device 70 .
Procedure ! CAUTION AAVs are biohazardous materials and must be handled according to governmental and institutional regulations. Experiments involving AAVs were performed using biosafety level 2 practices as required by the California Institute of Technology and the US Centers for Disease Control and Prevention. c CRITICAL The entire procedure spans 8 d, excluding pause points and the time required to evaluate transgene expression (Fig. 7a) . There are no pause points between days 1 and 5, until Step 11; once cells have been transfected, AAVs are harvested on days 3 and 5. Plan accordingly during this time window.
Triple transient transfection of HEK293T cells • Timing 1-2 h
c CRITICAL For capsids that package well (i.e., AAV9, AAV-PHP.B, AAV-PHP.eB, and AAV-PHP.S), the PEI transfection protocol typically yields ≥1 × 10 12 vg per 150-mm dish, as measured post purification 2, 3 . Before starting the protocol, determine the number of dishes needed per viral prep and use Supplementary Table 2 ('Transfection calculator' sheet) to calculate the quantities of PEI, DPBS, and plasmid DNA required for transfection. Skip to Step 43 if custom AAVs were obtained elsewhere. 1 24 h before transfection, seed HEK293T cells in 150-mm dishes to attain 80-90% confluency the next day 69 . Incubate the cells in a cell culture incubator at 37°C with 5% CO 2 . 2 At the time of transfection, make the PEI + DPBS master mix and the DNA + DPBS solution for each viral prep (Reagent setup and Supplementary Table 2 , 'Transfection calculator' sheet). Using a 5-or 10-ml serological pipette, add the required volume of the PEI + DPBS master mix (e.g., 'Transfection calculator' cell G9) dropwise to the DNA + DPBS solution (e.g., 'Transfection calculator' cells E9 + E11 + E13 + F9) while gently vortexing to mix. Cap the tube and thoroughly vortex for 10 s to mix. Allow the mixture to sit at RT for 2-10 min. Add 2 ml of the transfection solution dropwise to each dish and swirl to mix before returning the dishes to the cell culture incubator. c CRITICAL STEP We use a pAAV:pUCmini-iCAP-PHP:pHelper plasmid ratio of 1:4:2 based on micrograms of DNA. We use 40 µg of total DNA per 150-mm dish (5.7 µg of pAAV, 22.8 µg of pUCmini-iCAP-PHP, and 11.4 µg of pHelper) (Supplementary Table 2 , 'Detailed calculations' sheet). The plasmid ratio was optimized during the initial development of the AAV production protocol; 1:4:2 gave the best viral yields. c CRITICAL STEP The transfection solution will appear slightly cloudy because of the formation of DNA-PEI complexes 5, 6 . Allowing the mixture to sit for >10 min may reduce transfection efficiency. c CRITICAL STEP Users can opt to run a positive transfection/virus production control (e.g., pAAV-CAG-eYFP); this is especially important if using an untested rAAV genome. ? TROUBLESHOOTING 3 Change the media 12-24 h post transfection by aspirating the old media in 10% (vol/vol) bleach and replacing it with 20 ml of fresh, warmed media (Reagent setup). c CRITICAL STEP Do not allow the cells to remain without media for more than a few minutes. To protect the cells from unwanted stress, aspirate the media from five plates at a time and promptly replace it with new media. PEI is moderately cytotoxic 6 and cell death of up to 20% is common 71 . Do not allow the media to remain unchanged for more than 24 h post transfection. Failure to change the media in a timely manner will result in poor cell health and low titers. After scraping the first dish, prop it at a 30°angle, using an empty 1.5-ml microcentrifuge tube rack for support. Scrape down the residual cells and media such that they are pooled together. Return the dish lid and scrape the next plate; prop dishes up against one another along the length of the biosafety cabinet until scraping is complete. Use a 25-ml serological pipette to collect the media and cells from each dish; transfer to a 250-ml conical centrifuge tube. Pool the media and cells from up to 10 dishes in a single tube. ! CAUTION Scrape the cells with a forward motion (i.e., away from the front grill of the biosafety cabinet) to prevent media and cells from splashing out of the biosafety cabinet. If a spill does occur at this or any other step, immediately cover with paper towels and carefully saturate the towels with fresh 10% (vol/vol) bleach. c CRITICAL STEP To avoid cross-contamination, harvest the media and cells from one viral prep at a time. c CRITICAL STEP For larger viral preps (6-10 dishes), a 250-or 500-ml conical centrifuge tube can be used to harvest the media and cells (Steps 5-9). However, we recommend using two 250-ml tubes in Step 10B because the PEG pellet (Step 12) is difficult to remove from the walls and edges of 500-ml tubes (Step 14). secured. Centrifugation will result in the formation of a cell pellet (Fig. 7b ). 8 Pour off the supernatant (i.e., the clarified media) into the corresponding bottle from Step 4.
Allow excess media to drip back down onto the beveled edge of the 250-ml tube; remove using a P1000 pipette and add to the supernatant. Store the supernatant at 4°C until Step 10. c CRITICAL STEP Failure to remove excess media from the pellet will cause several milliliters of media to dilute the SAN digestion buffer in Step 9. 9 Cell pellet resuspension. Prepare 5 ml of SAN + SAN digestion buffer (Reagent setup) per viral prep. For smaller viral preps (1-5 dishes), use option A. For larger preps (6-10 dishes), use option B.
(A) Harvest from 1-5 dishes (i) Use a 5-ml serological pipette to gently resuspend the cell pellet in 5 ml of SAN + SAN digestion buffer; pipette into a 50-ml tube to finish resuspending the pellet (Fig. 7b) . (ii) Incubate in a 37°C water bath for 1 h and store at 4°C until Step 14 (up to 1 d) . c CRITICAL STEP Be sure to collect the entire pellet, which will stick to the walls and beveled edges of 250-ml tubes. Save the 250-ml tubes for Step 10. c CRITICAL STEP The high salt content of SAN digestion buffer lyses the cells, which release the viral particles and nucleic acids into the solution. Initially, the cell lysate may be viscous and difficult to pipette; SAN will degrade nucleic acids and reduce the viscosity after incubation at 37°C. The pH of the lysate will decrease to 8-9 or lower during cell lysis, but the lysate should appear pink rather than yellow/orange because of residual phenol red (Fig. 7b) . Note that the expression of fluorescent proteins from strong promoters (e.g., CAG) can alter the color of the lysate. c CRITICAL STEP (Optional) Collect a 30-µl sample from the cell lysate for troubleshooting; store at 4°C for up to 1 week. If the viral yield is lower than expected, the sample can be titered (Steps 32-42) to determine at which stage the virus may have been lost. ? TROUBLESHOOTING (B) Harvest from 6-10 dishes (i) Use a 10-ml serological pipette to partially resuspend the smaller cell pellet in 5 ml of SAN + SAN digestion buffer. Pipette into the second 250-ml tube containing the larger pellet and resuspend together; pipette into a 50-ml tube to finish resuspending the pellet (Fig. 7b) . (ii) Incubate in a 37°C water bath for 1 h and store at 4°C until Step 14 (up to 1 d).
c CRITICAL STEP Be sure to collect the entire pellet, which will stick to the walls and beveled edges of 250-ml tubes. Save the 250-ml tubes for Step 10. c CRITICAL STEP The high salt content of SAN digestion buffer lyses the cells, which release viral particles and nucleic acids into solution. Initially, the cell lysate may be viscous and difficult to pipette; SAN will degrade nucleic acids and reduce the viscosity after incubation at 37°C. The pH of the lysate will decrease to 8-9 or lower during cell lysis, but the lysate should appear pink rather than yellow/orange because of residual phenol red (Fig. 7b) . Note that expression of fluorescent proteins from strong promoters (e.g., CAG) can alter the color of the lysate. c CRITICAL STEP (Optional) Collect a 30-µl sample from the cell lysate for troubleshooting; store at 4°C for up to 1 week. If the viral yield is lower than expected, the sample can be titered (Steps [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Step 8 between the two corresponding 250-ml tubes from Step 9. c CRITICAL STEP (Optional) Collect a 30-µl sample from the media for troubleshooting; store at 4°C for up to 1 week. If the viral yield is lower than expected, the sample can be titered (Steps 32-42) to determine at which stage the virus may have been lost. 11 Use a 25-ml or 50-ml serological pipette to add a 1/5 final volume of 40% (wt/vol) PEG stock solution to the supernatant (i.e., the supernatant should contain a final concentration of 8% (wt/vol) PEG solution). Tighten the cap and thoroughly invert ten times to mix. Incubate on ice for 2 h. c CRITICAL STEP For AAV production in HEK293T cells, the cell culture media contains a large fraction of the expected yield 72 . Failure to PEG-precipitate AAV particles in the media will result in lower viral yields 8 . j PAUSE POINT The PEG-media mixture can be incubated at 4°C overnight. 12 Centrifuge the PEG-media mixture at 4,000g for 30 min at 4°C. Centrifugation will result in the formation of a PEG pellet (Fig. 7b) . 13 Pour off the supernatant (i.e., the PEG-clarified media) into a used media collection bottle for bleaching. Allow excess media to drip back down onto the beveled edge of the 250-ml tube; aspirate or pipette to remove. 14 PEG pellet resuspension. Prepare 1 ml of SAN + SAN digestion buffer (Reagent setup) per viral prep. For smaller viral preps (1-5 dishes), use option A. For larger preps (6-10 dishes), use option B.
(A) Harvest from 1-5 dishes (i) Use a P1000 pipette to carefully resuspend the PEG pellet in 1 ml of SAN + SAN digestion buffer; pipette into the corresponding lysate from Step 9 (Fig. 7b) . (ii) Incubate in a 37°C water bath for an additional 30 min. c CRITICAL STEP Resuspending the PEG pellet is difficult and will take~5 min per pellet. Be sure to collect the entire pellet, some of which will stick to the walls and beveled edges of 250-ml tubes. During resuspension, avoid air bubbles, which can be difficult to collect with a pipette and may disrupt capsid structure. Do not use a serological pipette to resuspend the pellet, which can become lodged within the barrel of the pipette. c CRITICAL STEP (Optional) Collect a 30-µl sample from the PEG pellet resuspension, before adding it to the corresponding lysate, for troubleshooting; store at 4°C for up to 1 week. If the viral yield is lower than expected, the sample can be titered (Steps 32-42) to determine at which stage the virus may have been lost. j PAUSE POINT Store the lysate at 4°C overnight. Alternatively, use a dry ice-ethanol bath to freeze the lysate; store at −20°C for up to 1 week. (B) Harvest from 6-10 dishes (i) Use a P1000 pipette to partially resuspend one of the PEG pellets in 1 ml of SAN + SAN digestion buffer. Pipette into the second 250-ml tube containing the second pellet and carefully resuspend together; pipette into the corresponding lysate from Step 9 (Fig. 7b) . (ii) Incubate in a 37°C water bath for an additional 30 min. c CRITICAL STEP Resuspending the PEG pellet is difficult and will take~5 min per pellet. Be sure to collect the entire pellet, some of which will stick to the walls and beveled edges of 250-ml tubes. During resuspension, avoid air bubbles, which can be difficult to collect with a pipette and may disrupt capsid structure. Do not use a serological pipette to resuspend the pellet, which can become lodged within the barrel of the pipette. c CRITICAL STEP (Optional) Collect a 30-µl sample from the PEG pellet resuspension, before adding it to the corresponding lysate, for troubleshooting; store at 4°C for up to 1 week. If the viral yield is lower than expected, the sample can be titered (Steps 32-42) to determine at which stage the virus may have been lost. j PAUSE POINT Store the lysate at 4°C overnight. Alternatively, use a dry ice-ethanol bath to freeze the lysate; store at −20°C for up to 1 week.
CRITICAL One iodixanol density gradient is sufficient to purify virus from up to ten 150-mm dishes. If more than ten dishes per prep are used, divide the lysate into more than one gradient. The AAV purification steps are most easily learned by visualization; refer to Fig. 8 and Supplementary Videos 1-3 for details. 15 Determine the number of gradients needed and prepare the iodixanol density gradient solutions (Reagent setup and Supplementary Table 3) . Set the OptiSeal tubes in the rack provided in the OptiSeal tube kit; alternatively, use the long edge of a 50-ml tube Styrofoam rack. c CAUTION Check the OptiSeal tubes for defects; tubes with dents may collapse during ultracentrifugation. 16 Pour the density gradients (Fig. 8a,b and Supplementary Video 1, 0:00-1:45, or Supplementary Video 2, 0:00-1:13). Each gradient is composed of the following layers: 6 ml of 15% (wt/vol) iodixanol, 6 ml of 25% (wt/vol) iodixanol, 5 ml of 40% (wt/vol) iodixanol, and 5 ml of 60% (wt/vol) iodixanol (Supplementary Table 3 ). Pour the layers with a 2-or 5-ml serological pipette. We typically use a 2-ml pipette; using a 5-ml pipette is faster but requires the use of PTFE and Tygon tubing and extra reagents. To load the layers with a 2-ml pipette, choose option A. To load the layers with a 5-ml pipette, choose option B.
(A) Loading with a 2-ml pipette (i) Begin by pipetting 6 ml (measure to the 3 ml mark twice) of 15% (wt/vol) iodixanol to each tube. Next, add 6 ml of 25% (wt/vol) iodixanol under the 15% layer by lightly touching the pipette tip to the bottom of the tube and slowly releasing the solution (Fig. 8a and Supplementary Video 1, 0:13-1:29). Continue adding layers of increasing density under the previous layer. The gradients should have a sharp delineation between layers (Fig. 8b) . c CRITICAL STEP When loading the 25%, 40%, and 60% layers with a 2-ml pipette, stop releasing the solution and slowly remove the pipette once the iodixanol is~5 mm from the tip of the pipette (Supplementary Video 1, 0:42-0:58 and 1:20-1:25). This will prevent an air bubble from disturbing the gradient. The remaining iodixanol will be released when the pipette is removed from the tube. c CRITICAL STEP Corning brand 2-ml serological pipettes consistently fit into OptiSeal tubes; other brands should be tested before use. ? TROUBLESHOOTING (B) Loading with a 5-ml pipette (i) Attach a piece of tubing (see Equipment) to a 5-ml pipette. Begin by pipetting 6 ml of 15% (wt/vol) iodixanol into each tube. Next, add 6 ml of 25% (wt/vol) iodixanol under the 15% layer by lightly touching the tubing to the bottom of the tube and slowly releasing the solution (Supplementary Video 2, 0:17-1:13). Continue adding layers of increasing density under the previous layer. The gradients should have a sharp delineation between layers (Fig. 8b) . c CRITICAL STEP Fill the 5-ml pipette with more layer solution than is needed (e.g., an extra 1 ml per layer); this will prevent an air bubble from disturbing the gradient when releasing the last of the required volume (Supplementary Video 2, 1:09-1:11). Remember to prepare extra solution (Reagent setup). ? TROUBLESHOOTING 17 Centrifuge the lysate from Step 14 at 2,000g for 10 min at RT. Centrifugation will result in the formation of a pellet (Fig. 7b ). 18 Use a 2-ml serological pipette to load the supernatant (i.e., the clarified lysate) (~6-7 ml total) from
Step 17 above the 15% (wt/vol) iodixanol layer ( Fig. 8c and Supplementary Video 1, 1:46-2:22 or Supplementary Video 2, 1:14-1:55). Touch the pipette tip to the surface of the 15% layer and slowly release the lysate such that a layer forms on top. c CRITICAL STEP Use a pipetting device with precise control. Do not allow the lysate to drip from the pipette tip onto the 15% layer; this will cause the lysate to mix with the gradient. Note that Corning brand 2-ml serological pipettes consistently fit into OptiSeal tubes; other brands should be tested before use. c CRITICAL STEP The pellet may be soft, making it difficult to retrieve all of the supernatant. After loading 6-7 ml of lysate above the 15% layer, spin the lysate for an additional 15 min at 3,000g at RT; use a P200 or P1000 pipette to slowly load the remaining supernatant onto the lysate layer. Discard the pellet in 10% (vol/vol) bleach or a biohazard waste bin. c CRITICAL STEP (Optional) Collect a 30-µl sample from the lysate for troubleshooting; store at 4°C for up to 1 week. If the viral yield is lower than expected, the sample can be titered (Steps 32-42) to determine at which stage the virus may have been lost. 19 Using a 2-ml serological pipette, fill each tube up to the neck with SAN digestion buffer. Firmly insert a black cap (Fig. 8d) and place a spacer on top (Fig. 8e) . Caps and spacers are provided with the OptiSeal tubes and in the OptiSeal tube kit, respectively. ! CAUTION Overfilling the tube can cause a spill when inserting the black cap. Handling the tubes without caps, or with loosely fitted caps, can also cause spills. ! CAUTION Avoid air bubbles, which can cause the OptiSeal tubes to collapse during ultracentrifugation. c CRITICAL STEP The black cap should fit right above or touch the lysate. 20 Weigh the tubes with the caps and spacers on. Balance the tubes to within 5-10 mg of each other using SAN digestion buffer. Be sure to adjust the tube weight in the biosafety cabinet; use the tube removal tool provided with the OptiSeal tube kit to remove the black cap and add the appropriate volume of SAN digestion buffer with a P20 or P200 pipette. ! CAUTION Failure to balance the tubes before ultracentrifugation could result in damaged equipment. 21 Place the ultracentrifuge rotor in the biosafety cabinet. Load the tubes and fasten the lid.
! CAUTION Ensure that the rotor is in proper working order. This includes checking that the o-rings are intact, as cracked o-rings can cause virus to spill during ultracentrifugation. Also, check that the rotor and tubes are completely dry; moisture between tubes and the tube cavity can cause tubes to collapse. To prevent damage to the rotor, set it on a paper towel so that the overspeed disk at the bottom is not scratched. 22 Carefully transfer the rotor to the ultracentrifuge. Spin the Type 70 Ti rotor at 350,000g (58,400 r.p.m.) for 2 h and 25 min at 18°C with slow acceleration (no. 3; the instrument will take 3 min to accelerate to 500 r.p.m., followed by maximum acceleration) and deceleration (no. 9; the instrument will deccelerate at maximum speed until it reaches 500 r.p.m., then take 6 min to stop) profiles. Alternatively, a Type 60 Ti rotor can be used at 358,000g (59,000 r.p.m.). ! CAUTION Always follow the manufacturer's instructions while operating an ultracentrifuge. 23 During ultracentrifugation, gather the supplies and equipment for Steps 24-27. Assemble the clamp setup (Equipment setup) and collect one of each of the following per gradient: Amicon Ultra-15 centrifugal filter device, 5-ml syringe, 10-ml syringe, 0.22-µm syringe filter unit, and a 16-gauge needle. 24 After ultracentrifugation, bring the rotor inside the biosafety cabinet and remove the lid. Use the spacer removal tool provided with the OptiSeal tube kit to remove the spacer from the first tube. Next, use the tube removal tool to grip the tube neck. Slowly remove the tube from the rotor and secure it into the clamp setup above a 500-ml or 1-liter beaker containing fresh 10% (vol/vol) bleach (Fig. 8f) . Clean the side of the tube with a paper towel or a Kimwipe sprayed with 70% (vol/vol) ethanol. ! CAUTION The black cap may become dislodged from the tube during removal, increasing the likelihood of a spill. Try replacing the cap before removing the tube from the rotor. Otherwise, replace the cap once the tube is secured in the clamp setup. ! CAUTION If a tube collapses during ultracentrifugation, take extra care when removing the tube from the rotor. Use fresh 10% (vol/vol) bleach to wipe the tube before proceeding with AAV purification. Viruses purified from collapsed tubes may have lower yields. ? TROUBLESHOOTING 25 Prepare the supplies for Steps 26 and 27. First, remove and save the plunger from a 10-ml syringe.
Attach a 0.22-µm syringe filter unit to the syringe barrel and place it on top of an Amicon filter device. Next, add 10 ml of DPBS to the barrel and allow the solution to begin dripping through the syringe filter unit and into the filter device (Fig. 8f) . Last, attach a 16-gauge needle to a 5-ml syringe. c CRITICAL STEP Amicon filter devices contain traces of glycerine. If this interferes with downstream applications, rinse the device with DPBS before use. (Optional) Rinse the filtration membrane of the Amicon filter device by adding 15 ml of DPBS to the top chamber and centrifuging at 3,000g for 1 min at RT; discard the flow-through. The manufacterer recommends using the device immediately after rinsing. 26 From the tube clamped in Step 24, collect the virus from the 40/60% interface and 40% layer 9, 10 ( Fig. 8g and Supplementary Video 3, 0:00-1:30). Hold the top of the OptiSeal tube with your nondominant hand; use your dominant hand to hold the needle/syringe. Use a forward-twisting motion to insert the needle~4 mm below the 40/60% interface (i.e., where the tube just starts to curve). Use the tube removal tool in your non-dominant hand to remove the black cap from the tube to provide a hole for air entry. With the needle bevel up, use the needle/syringe to collect 4.0-4.5 ml of virus/ iodixanol from the 40/60% interface and 40% layer. Do not collect from the white protein layer at the 25/40% interface; as this interface is approached, rotate the needle bevel down and continue collecting from the 40% layer. Firmly replace the black cap before removing the needle from the tube. ! CAUTION Keep your hands out of the path of the needle to prevent accidental exposure to AAVs. Failure to firmly replace the black cap before removing the needle will cause the AAVcontaminated solution to flow out of the needle hole in the tube and potentially onto and out of the biosafety cabinet. Perform this step over a large beaker of fresh 10% (vol/vol) bleach (Fig. 8f) . c CRITICAL STEP The virus should concentrate at the 40/60% interface and within the 40% layer 10 . There will not be a visible virus band, but the phenol red in the 25% and 60% layers helps to better define the 40% cushion. c CRITICAL STEP Before attempting to collect virus from the density gradient, practice on an OptiSeal tube filled with water. c CRITICAL STEP (Optional) Collect a 30-µl sample from the virus/iodixanol for troubleshooting; store at 4°C for up to 1 week. If the viral yield is lower than expected, the sample can be titered (Steps 32-42) to determine at which stage the virus may have been lost. ? TROUBLESHOOTING 27 Add the 4.0-4.5 ml of virus/iodixanol to the syringe barrel containing 10 ml of DPBS (prepared in
Step 25) (Fig. 8h and Supplementary Video 3, 1:31-2:06). Layer the virus below the DPBS by placing the needle near the bottom of the barrel and pressing on the plunger. Insert the 10-ml syringe plunger into the barrel and push the virus/DPBS mixture through the syringe filter unit and into the Amicon filter device (Supplementary Video 3, 2:07-2:32). Mix well using a P1000 pipette. c CRITICAL STEP This filtration step reduces the likelihood of clogging the filtration membrane in the Amicon filter device. The virus/iodixanol mixture will be difficult to push through the syringe filter unit; DPBS will be easy to push through as it washes the filter. c CRITICAL STEP AAVs adhere to hydrophobic surfaces, including plastics; use low-binding pipette tips (Reagents). Pluronic F-68 is a nonionic surfactant that may reduce virus loss associated with sticking to plastics. (Optional) Include 0.001% (vol/vol) Pluronic F-68 in the DPBS for Steps 27-30. 28 Centrifuge the virus/DPBS mixture at 3,000g for 5-8 min at RT, or until the volume of the solution remaining in the top chamber of the Amicon filter device is 500-1,500 µl (>10× concentrated). c CRITICAL STEP This step may take longer because iodixanol initially slows the passage of the solution through the filtration membrane. 29 Discard the flow-through for bleaching. Add 13 ml of DPBS to the virus in the top chamber and use a P1000 pipette to mix. c CRITICAL STEP Remove the filter device, which contains the virus, before discarding the flowthrough. 30 Centrifuge the virus/DPBS mixture as in Step 28. Wash the virus two more times for a total of four buffer exchanges. During the last spin, retain 300-500 µl of solution in the top chamber. c CRITICAL STEP The third and fourth washes may require only a 2-3-min spin until the desired volume remains in the top chamber. c CRITICAL STEP The volume retained in the top chamber will affect the final virus concentration (vg/ml) (i.e., the lower the volume, the higher the concentration). A final volume of 300-500 µl should work for most applications, assuming a production efficiency of at least 1 × 10 12 vg/dish and a dose and injection volume of no more than 1 × 10 12 vg and 100 µl, respectively (see 'Experimental design' section and Step 43 for dose and injection volume recommendations, respectively). For direct injections, a final volume of 200 µl may be optimal. Note that retaining too low a volume may cause the virus to aggregate during storage at 4°C (see Step 42 for details). 31 Use a P200 pipette to transfer the virus from the top chamber of the Amicon filter device directly to a 1.6-ml screw-cap vial; store at 4°C. c CRITICAL STEP Amicon filter devices are not sterile. If this is a concern for specific applications, the virus can be filter-sterilized before storage. (Optional) Filter-sterilize the virus. Use a P200 pipette to transfer the virus from the top chamber of the Amicon filter device directly to a Costar Spin-X filter unit within a centrifuge tube. Centrifuge the virus at 3,000g for 1 min at RT. Discard the filter unit and transfer the purified virus from the centrifuge tube to a 1.6-ml screw-cap vial; store at 4°C. c CRITICAL STEP The screw-cap vials are not low protein binding; however, they help prevent the formation of aerosols when opening and closing the tubes. We store AAVs in screw-cap vials at 4°C and typically use them within 3 months, during which time we have not noticed a decrease in titers or transduction efficiency in vivo. We have not rigorously tested the effects of long-term storage at −20°C or −80°C for systemically delivered viruses. ? TROUBLESHOOTING j PAUSE POINT Store the purified virus at 4°C for up to 3 months.
AAV titration • Timing 1 d
c CRITICAL The AAV titration procedure below is adapted from ref. 11 . Each virus sample is prepared in triplicate in separate 1.5-ml DNA/RNA LoBind microcentrifuge tubes and later loaded into a 96-well plate for qPCR. All solutions must be accurately pipetted and thoroughly mixed; qPCR is highly sensitive to small changes in DNA concentration. 32 Prepare a plan for the PCR plate setup. Allocate the first 24 wells (A1-B12) for the DNA standards such that standard no. 1 occupies wells A1-A3, standard no. 2 occupies wells A4-A6, and so on. Use the remaining wells for the virus samples such that the first virus sample occupies wells C1-C3, the second sample occupies wells C4-C6, and so on. c CRITICAL STEP Include DPBS as a negative control and a virus sample with a known concentration as a positive control; prepare the controls with the virus samples in Steps 33-40. 33 Use DNase I to digest DNA that was not packaged into the viral capsid. Prepare DNase I + DNase digestion buffer (Reagent setup) and add 100 µl to each 1.5-ml tube. Vortex each virus for 1-2 s to mix; alternatively, use a P200 pipette to mix. Add 2 µl of the virus to each of three tubes. Vortex for 1-2 s to mix and spin down (2,000g, RT, 10 s); incubate in a 37°C water bath for 1 h. c CRITICAL STEP Do not vortex/pipette the virus vigorously or vortex longer than 1-2 s; exposure to force may disrupt capsid structure. c CRITICAL STEP When dipping the pipette tip into the virus stock, insert the tip just below the surface of the liquid rather than dipping it deep inside. Excess virus carried on the outside of the tip will carry over into the DNase digestion buffer and cause variations in the titer. Step 1: 95°C, 10 min
Step 2: 95°C, 15 s
Step 3: 60°C, 20 s
Step 12 ; however, tail-vein injections appear to result in similar AAV distribution 16, 47 . c CRITICAL When possible, verify viral transduction and transgene expression in vitro before systemic administration. Note that co-injecting AAVs with other substances (e.g., dyes) could affect infectivity in vivo and should be tested independently. c CRITICAL Re-titer viruses before injection if more than 1 month has passed since titration; this will ensure that animals are administered the most accurate dose possible. 43 Determine the dose of virus to administer per mouse (see 'Experimental design' section for recommendations). Divide the dose (vg) by the titer (vg/ml) (Supplementary Table 4 , cell G27) to calculate the volume of virus needed to inject one mouse. In a screw-cap vial, prepare a master mix of virus based on the number of animals to be injected; briefly vortex each virus and master mix for 1-2 s before use. Transport the virus on ice once it is ready for injection. ! CAUTION Do not inject more than 10% of the mouse blood volume, which corresponds to 150 µl for a 25-g mouse. c CRITICAL STEP Depending on the user, it is easiest to inject 40-80 µl/mouse. If <40 µl/mouse is required, use DPBS or saline to dilute the virus such that a larger volume is injected. If more than 80 µl/mouse is required, it may be more convenient to re-concentrate the virus or perform two separate injections; follow institutional guidelines for multiple eye injections. Virus will be lost in the event of an unsuccessful injection; therefore, prepare more master mix than is required. c CRITICAL STEP To reduce the chance of contaminating the virus stock, avoid using the original virus stock; bring only an aliquot of what is needed for the injections. c CRITICAL STEP Do not store diluted viruses; only dilute what is needed immediately before injection. ? TROUBLESHOOTING 44 Assemble the anesthesia system 70 (Equipment setup) inside the biosafety cabinet. 45 Remove the mouse from its cage and place it in the induction chamber. Anesthetize the mouse with 1-5% isoflurane in oxygen. ! CAUTION Isoflurane must be handled according to federal, state, and local regulations. 46 While the mouse is being induced, load an insulin syringe with virus. Remove the dead space in the syringe barrel by gently ejecting the virus back into the tube such that air bubbles are expelled. Load the syringe again and repeat the procedure until no bubbles remain in the barrel. ! CAUTION Introducing air into the vascular system can be fatal. c CRITICAL STEP Introducing air into the virus may cause protein denaturation; perform this step gently and only until no bubbles remain in the syringe barrel. 47 Remove the anesthetized mouse from the induction chamber. Place the animal in a prone position on a small stack of paper towels. Position the mouse such that its head is situated on the same side as the operator's dominant hand. Place the nose cone on the mouse to maintain anesthesia. 48 Use the index finger and thumb of the non-dominant hand to draw back the skin above and below the eye, causing the eye to slightly protrude from the socket 12 .
With the dominant hand, insert the needle, bevel down, at a 30-45°angle into the medial canthus and through the conjunctival membrane. The needle should be positioned behind the globe of the eye in the retro-orbital sinus. Slowly release the virus into the sinus and gently remove the needle. ! CAUTION Assess anesthetic depth by loss of pedal reflex (via toe pinch) before inserting the needle into the retro-orbital sinus. Any movement of the eye or skin when the needle is inserted indicates incorrect needle placement. Keep hands out of the path of the needle to prevent accidental exposure to AAVs. Do not recap needles; discard into an approved biohazardous sharps container immediately after use. 57 of whole organs or animals, respectively, or another clearing method (e.g., ScaleSQ 64 ). Ensure that the chosen clearing protocol is compatible with the fluorescent protein(s) under investigation (see 'Experimental design' and 'Anticipated results' sections for details). Native fluorescence can be visualized using a fluorescence microscope (e.g., Keyence BZ-X700), confocal microscope (e.g., Zeiss LSM 880), or light-sheet microscope (e.g., custom-made 57 or LaVision BioTec UltraMicroscope II), depending on the tissue volume and desired imaging resolution. For experiments without fluorescent labels, evaluate transgene expression using molecular (e.g., qPCR 3 or Western blot 58 ), histological 57 (e.g., with antibodies or molecular probes), or functional (e.g., optical imaging 56 ) methods relevant to the experimental aims. Regardless of the approach used to evaluate gene expression, cell type-specific promoters should be verified at this stage in the protocol; we typically assess cell morphology and/or use antibody staining to confirm specificity 2 (Fig. 2b,c) . ? TROUBLESHOOTING
Troubleshooting
Troubleshooting advice can be found in Table 3 . Table 4 , 'Example' sheet). This is normal; the qPCR does not need to be repeated DNA standards degraded and/or stuck to the walls of 1.5-ml tubes Repeat the qPCR; prepare the DNA standard dilutions fresh, immediately before use, and use only DNA/RNA LoBind microcentrifuge tubes. Note that at low concentrations (high Ct values), standard nos. 1 and 2 will deviate from linearity (Supplementary Table 4 , 'Example' sheet). This is normal; the qPCR does not need to be repeated Viral yield is lower than expected (Supplementary Table 4 , cell K27) Transfection, AAV harvest, AAV purification, and/or AAV titration were not successful Include a positive transfection/virus production control (e.g., pAAV-CAG-eYFP) and a positive titration control. To determine at which stage the virus may have been lost, collect a 30-µl sample from the cell lysate (Step 9), the media before PEG precipitation (Step 10), the PEG pellet resuspension (Step 14) , and the lysate before (Step 18) and after iodixanol purification (Step 26) . Store samples at 4°C for up to 1 week for titering (Steps 32-42) AAV capsid and/or genome results in poor production efficiency Scale up viral preps to ensure enough virus is produced for downstream applications ITRs underwent recombination during bacterial growth After plasmid purification, but before transfection, digest pAAVs with SmaI to confirm the presence of ITRs, which are required for replication and encapsidation of the viral genome; always propagate pAAVs in recombination-deficient bacterial strains 43 (intravenous injection)
A large volume (e.g., more than 100 µl, depending on user preference) of virus needs to be injected Virus concentration is too low Reconcentrate the virus using an Amicon filter device. Add 13 ml of DPBS and the virus to the top chamber of the Amicon filter device and use a P1000 pipette to mix. Centrifuge at 3,000g at RT until the desired volume of solution remains in the top chamber 48 (Intravenous injection)
Virus spills out of the eye during injection Incorrect needle placement Absorb the spilled virus using a paper towel; disinfect AAV-contaminated surfaces and materials with fresh 10% (vol/vol) bleach or an equivalent disinfectant. Load the same insulin syringe with more virus, position the needle behind the globe of the eye in the retro-orbital sinus, and try the injection again. Practice injections using DPBS or saline until comfortable with the procedure 
AAV production
For capsids that package well (i.e., AAV-PHP.B, AAV-PHP.eB, and AAV-PHP.S), the AAV production protocol typically yields ≥1 × 10 12 vg per 150-mm dish 2, 3 . Production efficiency can be determined for each virus in Step 42 (Supplementary Table 4 , cell K27). Note that yields may vary Use a different fluorescent protein with similar spectral properties but higher photostability (e.g., tdTomato rather than mRuby2, or eGFP rather than Emerald) Lipofuscin accumulation Aging tissue Reduce autofluorescence using histological methods (e.g., Sudan black) or, if possible, inject younger adults (≤8 weeks old) and determine the minimum time required for transgene expression from prep to prep and genome to genome. Users can gauge production efficiency for each experiment by running a positive control (e.g., pAAV-CAG-eYFP).
Evaluation of transgene expression
For most applications, users can expect to assess transduced cells beginning 2 or more weeks after intravenous injection (see 'Experimental design' section for details). The chosen method for evaluating transgene expression will vary from user to user and may involve molecular, histological, and/or functional approaches 59 ( Step 50). We typically use fluorescent reporters to assess gene expression in thick (≥100 µm), cleared tissue samples; below, we discuss expected results for the applications presented here (Figs. 2-5 ) and in our previous work 2, 3 . Commonly used reporters such as GFP, eYFP, and tdTomato show strong fluorescent labeling in PACT-and PARS-cleared tissues, enabling whole-organ and thick-tissue imaging of transgene expression 3, 57, 60 . Most markers, including mTurquoise2, mNeonGreen, and mRuby2, can also be detected after mounting labeled tissues in optical clearing reagents such as RIMS 57 or ScaleSQ 64 ( Figs. 3a,c,d , 4b-d and 5e) or commercially available mounting media (Fig. 5a,c) . Depending on the rAAV genome, fluorescent proteins can be localized to distinct cellular compartments, including the nucleus (via NLS) (Fig. 2a,b) , cytosol (Figs. 2d,e, 3, 4b and 5), and cell membrane (via farnesylation 76 or fusion to a membrane protein such as ChR2) (Figs. 3d and 4d) . In summary, we present a comprehensive protocol for the production and administration of AAV-PHP viruses. We have validated the ability of AAV-PHP variants to provide efficient and noninvasive gene delivery to specific cell populations throughout the body. Together, this AAV toolbox equips users with the resources needed for a variety of applications across the biomedical sciences.
